Overview

A Study of Zanubrutinib in Patients With ITP

Status:
Recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

This project was undertaken to evaluate the efficacy and safety of BTK inhibitor Zanubrutinib for the secondary treatment of adults with primary immune thrombocytopenia (ITP).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Peking University People's Hospital

Treatments:

Zanubrutinib